NCT06442475View on ClinicalTrials.gov

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 29, 2024

Primary Completion Date

August 12, 2026

Study Completion Date

February 12, 2027

Conditions
Ann Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood, oral, and/or rectal sample collection

PROCEDURE

Computed Tomography

Undergo PET/CT or CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

BIOLOGICAL

Mosunetuzumab

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER